C3 glomerulopathy: diagnostic algorithm in pregnancy
PDF (Español (España))

Keywords

pregnancy
glomerulonephritis
kidney disease
diagnostic techniques and procedures
C3 glomerulopathies
diagnosis
differential

How to Cite

1.
Roselli Sanmartín C, Torres Serrano RE, Escobar Orozco C, Jara AM, Mendoza Orozco JE, Rodríguez Acosta MJ. C3 glomerulopathy: diagnostic algorithm in pregnancy. Rev. Colomb. Nefrol. [Internet]. 2022 Jan. 20 [cited 2022 May 18];9(1):e378. Available from: https://revistanefrologia.org/index.php/rcn/article/view/378

Abstract

Glomerular disease involves a heterogeneous group of entities that are characterized by loss of the ar-chitecture and function of the glomerulus and this can be caused by immunity, infectious and paraneoplastic etiologies. The aforementioned can be identified in histopathological studies. The recognition ofthis entity during pregnancy represents a diagnostic challenge due to the superposition of physiological changes, the development of autoimmune diseases and / or genetic disease, among others. Clinicalmanifestations can be into specific syndromic groups; however we can find indistinguishable manifes-tations and overlapping of this. When the disease is present its common to find rapidly establishmentand unfavorable evolution about renal function. With this it’s necessary to complete studies involvingthe initial clinical approach until histopathological findings with the goal to find primary and secondarycauses. As it’s known primary glomerulonephritis is not the most frequent in pregnancy, the accuracyin the diagnosis and the proper classification allows the direct and soon management. In this case reportwe describe 2 pregnant women with primary glomerular disease with discrepancy in their diagnosis.We talk about manifestations during pregnancy, the algorithm used in the diagnosis and nally theinitial treatment and the maintenance used in these patients.

https://doi.org/10.22265/acnef.9.1.378
PDF (Español (España))

References

Couser WG. Glomerulonephritis. Vol. 353, Lancet. Elsevier Limited; 1999. 1509–15. DOI: https://doi.org/10.1016/S0140-6736(05)75849-9

González L, Cantillo J. Diagnóstico en enfermedad glomerular del adulto. Acta Médica Colombiana. 2013; 38:101–7. DOI: https://doi.org/10.36104/amc.2013.294

García Herrera HG, Restrepo Valencia CA, Buitrago Villa CA. Características clínicas e histológicas de las enfermedades parenquimatosas renales en una muestra de biopsias renales obtenidas entre el año 2002 y el 2017 en el departamento de Caldas, Colombia. Revista colombiana de nefrologia. 2018; 2:107-117. DOI: http://dx.doi.org/10.22265/acnef.0.0.300

Blom K, Odutayo A, Bramham K, Hladunewich MA. Pregnancy and glomerular disease: A systematic review of the literature with management guidelines. Clinical Journal of the American Society of Nephrology. 2017. 12; 1862-1872. DOI: https://doi.org/10.2215/CJN.00130117

Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmunity Reviews. 2014. 13; 723-9. DOI: https://doi.org/10.1016/j.autrev.2014.02.007

Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nature Reviews Nephrology. 2019. 15; 129–143. DOI: https://doi.org/10.1038/s41581-018-0107-2

Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, et al. New approaches to the treatment of dense deposit disease. Journal of the American Society of Nephrology. 2000. 18; 2447–2456. DOI: https://doi.org/10.1681/ASN.2007030356

Pickering MC, D’agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: Consensus report. In: Kidney International. 2013. 84; 1079–1089. DOI: https://doi.org/10.1038/ki.2013.377

Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic. Mayo Clin Proc. 2018. 93; 991-1008. DOI: https://doi.org/10.1016/j.mayocp.2018.05.019

Khalighi MA, Wang S, Henriksen KJ, Bock M, Keswani M, Meehan SM, et al. Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy. Clin Kidney J. 2016. 9; 397–402. DOI: https://doi.org/10.1093/ckj/sfw032

Aringer, M. et al. European League Against Rheumatism/American College ofRheumatology classication criteria for systemic lupus erythematosus. Arthritis &Rheumatology, Arthritis Rheumatol. 2019. 71;1400-1412. DOI: https://doi.org/10.1136/annrheumdis-2018-214819

Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85; 450–456 2014. DOI: https://doi.org/10.1038/ki.2013.340

Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015; 26: 2011-2022. DOI: https://doi.org/10.1681/ASN.2014050459

Smyth A, Oliveira G, Lahr B, Bailey K, Norby S, Garovic V. A systematic review and meta-analysis ;of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clinical Journal of the American Society of Nephrology, 2010; 5: 2060-2068. DOI: https://doi.org/10.2215/CJN.00240110

Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun. 2016; 74: 6–12. DOI: https://doi.org/10.1155/2018/2413637

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. In: Kidney International. 2019; 95: 281-295. DOI: https://doi.org/10.1016/j.kint.2018.11.008

Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88:1153-60. DOI: https://doi.org/10.1038/ki.2015.227

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol. 2018; 13: 406–413. DOI: https://doi.org/10.2215/CJN.09080817

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.